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Determining intra-tumoral heterogeneity and immune escape mechanisms in
melanoma using spatial transcriptomics
Y Lim1, S Kang2, H Kim3, J Mun1, M Roh4, N Gulati5, H Yang6, J Moon7, C Won6 and C Park2
1 Department of Dermatology, Seoul National University Hospital, Jongno-gu, Seoul, Korea
(the Republic of), 2 Department of Biomedical Sciences, Seoul National University College
of Medicine, Seoul, Korea (the Republic of), 3 Genomic Medicine Institute, Medical
Research Center, Seoul National University College of Medicine, Seoul, Korea (the Republic
of), 4 Department of Dermatology, Yonsei University College of Medicine, Seodaemun-gu,
Seoul, Korea (the Republic of), 5 Department of Dermatology, Icahn School of Medicine at
Mount Sinai, New York, New York, United States, 6 Department of Dermatology, Asan
Medical Center, Songpa-gu, Seoul, Korea (the Republic of) and 7 Samsung Genomic Institute, Samsung Medical Center, Gangnam-gu, Seoul, Korea (the Republic of)
Melanoma, like other cancers, originates from a single clone. As the cancer progresses, the
tumor thickens and immune evasion ensues. However, few studies have investigated the
mechanisms involved in these processes using spatial transcriptomics. We aimed to elucidate
genetic and transcriptional heterogeneity in relation to melanoma thickness and to explore
the molecular mechanisms related to immune escape. Five punch-biopsied fresh tissue
samples and saliva were obtained from a single patient and used for paired whole exome
sequencing. The subsequent excision specimen was prepared for formalin-fixed paraffinembedded block and profiled using spatial transcriptomics. DNA-level mutation accumulation was commensurate with the thickness of the melanoma. Spatial transcriptome analysis
indicated that immune evasion involves changes in antigen presentation as well as defects in
b2-microglobulin and human leukocyte antigen class I processing. Levels of these molecules,
which are critical for T cell recognition of tumor antigens, tended to significantly decrease as
the melanoma depth increased. We also found that the expression of caspases and interferon
alpha inducible protein-encoding genes inversely correlated with tumor thickness. The study
was based on sampling a lesion from a single patient. Spatial transcriptomics can increase our
mechanistic understanding of tumor immune escape.

Comparison of S100A8 and PRAME as biomarkers for diagnosing melanoma
J Hai1, SL Wong1, Y Li3, DL Migloretti3, MA Fung1,2 and M Kiuru1,2 1 Dermatology, University of California Davis Health System, Sacramento, California, United States, 2 Pathology
and Laboratory Medicine, University of California Davis Health System, Sacramento, California, United States and 3 Public Health Sciences, University of California Davis Health
System, Sacramento, California, United States
Early diagnosis of melanoma is crucial to improved patient prognosis but can be difficult to
achieve from histopathology alone. PRAME is used increasingly in dermatology as an
ancillary tool to help differentiate between benign vs. malignant melanocytic tumors. S100A8
is another biomarker found to be expressed in melanoma-associated epidermal keratinocytes,
but its diagnostic utility has not been compared to other biomarkers, including PRAME. In this
retrospective case-control study, we compared S100A8 and PRAME immunohistochemistry
(IHC) in melanocytic nevi and melanoma (n¼209). An S100A8 and PRAME IHC score were
assigned to each tumor sample, indicating the proportion of tumor-associated epidermis
stained or the proportion of tumor cells stained, respectively. S100A8 IHC scores were previously reported (Kiuru et al., 2021). We analyzed diagnostic accuracy in detecting melanoma and melanoma in situ by using receiver operating characteristic curves, which showed
an area under the curve (AUC) of 0.8326 for S100A8 and 0.8741 for PRAME. These AUCs
were both significantly greater than chance, or AUC¼0.5 (p<0.001), but not significantly
different from each other (p¼0.22). For S100A8, when a positive test was defined as a score of
4 or 5 (>50% of tumor-associated epidermis stained), the sensitivity was 42.42%, and
specificity was 98.18%. For PRAME, when a positive test was defined as a score of 3 (>50%
of tumor stained), the sensitivity was 79.80%, and the specificity was 87.27%. When a
positive test was defined as >50% of tumor stained for both S100A8 and PRAME, sensitivity
was 39.39%, and specificity was 99.09%. Thus, both biomarkers are useful for accurately
detecting malignant melanocytic tumors. When combined with PRAME, S100A8 increases
specificity, demonstrating the utility of S100A8 when interpreted alongside other histopathological features and ancillary tests.
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Comparison of soluble proteins from skin sections of acne and TCA induced
postinflammatory hyperpigmentation and erythema
N Karaman-Jurukovska1, IH Hamzavi2, I Kohli2, C Nicholson2, T Mohammad2, A Nahhas2,
T Braunberger2, M Matsui1 and T Mammone1 1 Estee Lauder Companies, New York, New
York, United States and 2 Department of Dermatology, Henry Ford Health System, Detroit,
Michigan, United States
Postinflammatory hyperpigmentation (PIH) is an acquired hypermelanosis occurring after
cutaneous inflammation or injury that can arise in all skin types, but more frequently affects
skin-of-color. The differences in the ethology of PIH and Postinflammatory erythema (PIE) in
skin of color were evaluated from soluble protein extracts collected from skin section samples, using Somascan protein kit1.3 k (n¼5). The skin samples were collected from selected
gluteal TCA-induced lesions and truncal acne pustules, of either PIH or PIE, at day 28 post
initial evaluation. Differences between proteins (FDR<0.05) from PIH and PIE were analyzed
with STRING version 11.5 and analysis points toward involvement of JAK/STAT signaling
pathway and enhanced IL17 signaling in PIH compared to PIE lesions (OSM, CSF3, IL10RA,
IL12RB2, IL10RB, IL3, CSF2, IL17D, IL17F, IFNA2, IFNA10, CRLF2, IL5RA, TYK2, IL12RB1,
PRLR, GHR). The involvement of JAK/STAT signaling pathway has been described for some
chronic cutaneous inflammatory conditions and acne. A higher occurrence of dermal
remodeling proteases and inhibitors were found in PIE (MMP1, MMP2, MMP7, TIMP2)
indicating a dermal remodeling phase at the time of excision. Concurrently, elevated levels of
IL-1b, and TGF-b (critical for triggering and continuing differentiation programs of naı̈ve
CD4+ T cells to IL-17 secreting Th17 cells) in PIH samples suggests continuing promotion of
macrophage infiltration and sustained inflammation. In addition to MMP13 and MMP16, the
protein Keap1 was found to be increased in the PIH samples. Keap1, a repressor of master
cellular defense against oxidative and electrophilic stresses, has been reported to be involved
in the imbalance of proteolysis that can lead towards premature aging and in a senescent
phenotype of endothelial cells. The sustained inflammation with excess of Keap1 protein
might contribute to an altered proteostasis and ethology of PIH.

Depletion of senescent cells improves targeted therapy outcome in melanoma
R Perez-Lorenzo1, EY Lee1, SO Erjavec1,2 and AM Christiano1,2 1 Dermatology, Columbia
University, New York, New York, United States and 2 Genetics and Development, Columbia
University, New York, New York, United States
Cellular senescence is a non-proliferative but viable state that can be induced by oncogene
expression and anti-cancer therapeutics, such as BRAF inhibition, and has long been
considered a beneficial tumor suppressive mechanism. However, senescent cells express a
well-characterized senescence-associated secretory phenotype (SASP), which may contribute
to an immunosuppressive microenvironment and an increased malignant phenotype, leading
to tumor recurrence and metastasis. To investigate the role of senescent cells in tumor growth,
we treated B1610 (B16) melanoma cells in vitro with the senolytic drug ABT737 or vehicle
control and injected 5x104 viable cells into syngeneic mice. We found that senolytic pretreated B16 cells grew into significantly smaller tumors compared to controls. Tumors from
senolytic-treated cells had significantly fewer senescence-associated b-galactosidase and p16
expressing cells, which correlated with decreased SASP expression, and reduced tumor
infiltration of myeloid-derived suppressor cells. We next treated BRAF mutant human melanoma cells in vitro with the BRAF inhibitor PLX4720, and found a significant increase in the
number of senescent cells and expression of SASP members such as IL-1b, IL-6, and IL-8, a
phenomenon known as therapy-induced senescence. Further, there was a significant increase
in apoptotic cells when treated with a combination of PLX4720 and ABT737, suggesting that
this combination may be more effective for tumor eradication than BRAF inhibition alone. We
then asked whether eliminating senescent cells with senolytic drugs enhanced tumor control
by BRAF inhibition anti-cancer therapy. We treated YUMM1.7 subcutaneous tumors with
PLX4720 and the senolytic drug ABT263 and showed a durable repression of tumor regrowth
compared to controls. Our findings suggest that therapy-induced senescence is a potential
mechanism for acquired resistance and evasion of anti-tumor immune responses, which can
be overcome by depleting senescent cells with senolytic drugs.
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Reprogramming the tumor microenvironment by a second-generation
recombinant modified vaccinia virus Ankara
S Liu1, G Mazo1, N Yang1, T Zhang2, SB Tariq1, Y Wang1, D Hirschhorn-Cymerman1, L Ji1,
A Tan2, J Wang3, W Yan4, J Choi4, A Rossi1, JZ Xiang2, MO Li1, T Merghoub1, JD Wolchok1
and L Deng1 1 Memorial Sloan Kettering Cancer Center, New York, New York, United States,
2 Weill Cornell Medicine, New York, New York, United States, 3 Genvira Biosciences,
Ottawa, Ontario, Canada and 4 IMVAQ Therapeutics, Sammamish, Washington, United
States
Immune checkpoint blockade (ICB) therapy has brought hope to many cancer patients, but
the response rate is low in many cancer types, and acquired resistance to ICB can develop
over time. Oncolytic viruses are promising therapeutic agents for advanced cancers. Modified
vaccinia virus Ankara (MVA) is an attenuated, replication-deficient poxvirus safe for human
use, making it a favorable platform for cancer immunotherapy. Our first-generation recombinant MVA has shown promising antitumor efficacy in multiple murine tumor models due to
the deletion of the E5R gene (encoding an inhibitor of the DNA sensor cGAS) from the MVA
genome and the insertion of two membrane-anchored transgenes e Flt3L and OX40L, which
leads to the activation of the host innate and adaptive antitumor immunity. Here in this study,
we engineered our second-generation recombinant MVA (MQ833) with the deletion of two
more viral immune evasion genes e E3L and WR199, and the insertion of IL12 anchored to
the extracellular matrix to mitigate toxicity. Intratumoral (IT) delivery of MQ833 resulted in an
80-100% cure in the mouse B16-F10 melanoma model, which is dependent on nucleic acidsensing and IFN signaling pathways. Single-cell RNA sequencing analysis revealed that IT
MQ833 injection reprogrammed the tumor microenvironment into an immune-stimulating
state, by activating CD8+ and CD4+ T cells, depleting regulatory T cells, recruiting and
activating neutrophils, and polarizing M1 macrophages. Interestingly, MQ833 treatment
cured 70% of B2m knock-out melanomas likely due to combined effects of IL-12 and type I
and II IFN. Loss of MHC-I is the most common mechanism of tumor resistance to ICB. Hence,
our results support the use of MQ833 for ICB-resistant tumors.

Identification and functional implication of variants associated with skin
pigmentation in Chinese population
X Cai1, X Liu2, Y Zhao1, K Xu2, W Li1, Z Yang2 and S Wang1 1 Chinese Academy of Sciences
Shanghai Institute of Nutrition and Health, Shanghai, Shanghai, China and 2 Academy of
Medicine Science, Zhengzhou University, Zhengzhou, China
Skin pigmentation is a major feature of skin, and a marker associated with beauty, health and
aging. Among the past genome-wide association studies on skin pigmentation, a relatively
small proportion have focused on Chinese population. Large-scaled studies based on
measured skin pigmentation phenotypes are particularly rare in Chinese and other East Asian
populations. In the Jidong cohort study (N ¼ 3,544), we measured the skin pigmentation on
low-exposed area with colorimeter and performed genome-wide scans on skin color and
melanin index. We identified associated loci on 9p22.2, 10q26.11, 12q21.33, 15q12.6 and
15q13.1, and validated in independent cohorts. Functional annotation and luciferase report
assays revealed evidence for the top SNP on 12q21.33 functioning as an enhancer, and
regulating pigmentation-related gene TMTC3, although in previous studies, this top SNP has
been mapped to the nearby gene KITLG, another well-known pigmentation-related gene.
From publicly available database, we found further evidence suggesting regulation pathway
on how TMTC3 altering skin pigmentation. This study provided additional insight into the
genetics underlying skin pigmentation.
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